Send to

Choose Destination
Springerplus. 2013 Jul 4;2(1):301. doi: 10.1186/2193-1801-2-301. Print 2013 Dec.

What makes cancer stem cell markers different?

Author information

Glycotope GmbH, Robert-Rössle-Str.10, D-13125 Berlin-Buch, Germany.


Since the cancer stem cell concept has been widely accepted, several strategies have been proposed to attack cancer stem cells (CSC). Accordingly, stem cell markers are now preferred therapeutic targets. However, the problem of tumor specificity has not disappeared but shifted to another question: how can cancer stem cells be distinguished from normal stem cells, or more specifically, how do CSC markers differ from normal stem cell markers? A hypothesis is proposed which might help to solve this problem in at least a subgroup of stem cell markers. Glycosylation may provide the key.


Cancer stem cells; Glycosylation; Stem cells; Therapeutic targets; Thomsen-Friedenreich antigen

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center